颌骨骨坏死的潜在病理生理学机制。
Potential pathophysiological mechanisms in osteonecrosis of the jaw.
机构信息
University of Connecticut Health Center, Division of Oral and Maxillofacial Surgery, School of Dental Medicine, Farmington, Connecticut, USA.
出版信息
Ann N Y Acad Sci. 2011 Feb;1218:62-79. doi: 10.1111/j.1749-6632.2010.05835.x.
Abstract
Bisphosphonates are used in the treatment of hypercalcemia of malignancy, skeletal complications associated with metastastic bone disease, Paget's disease, and osteoporosis. Osteonecrosis of the jaw (ONJ) is a recently described clinical condition that has been associated with the use of nitrogen-containing bisphosphonates. Reports describing this entity first appeared in the literature in 2003. While there have been significant numbers of case reports and a limited number of retrospective and prospective studies examining risk factors associated with ONJ, the pathophysiology of this condition remains elusive. In this review, we explore proposed mechanisms underlying ONJ development and identify potential areas for future investigation.
摘要
双膦酸盐用于治疗恶性高钙血症、转移性骨病相关的骨骼并发症、佩吉特病和骨质疏松症。颌骨坏死（ONJ）是一种新描述的临床病症，与使用含氮双膦酸盐有关。描述该病症的报告于 2003 年首次出现在文献中。虽然有大量的病例报告，以及有限数量的回顾性和前瞻性研究检查了与 ONJ 相关的危险因素，但该病症的病理生理学仍然难以捉摸。在这篇综述中，我们探讨了 ONJ 发展的潜在机制，并确定了未来研究的潜在领域。
相似文献
1
Potential pathophysiological mechanisms in osteonecrosis of the jaw.颌骨骨坏死的潜在病理生理学机制。
Ann N Y Acad Sci. 2011 Feb;1218:62-79. doi: 10.1111/j.1749-6632.2010.05835.x.
2
Bisphosphonates and osteonecrosis of the jaws: science and rationale.双膦酸盐与颌骨骨坏死：科学依据与原理
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Aug;104(2):186-93. doi: 10.1016/j.tripleo.2006.12.004. Epub 2007 Apr 20.
3
A review of the clinical implications of bisphosphonates in dentistry.双膦酸盐在牙科中的临床意义综述。
Aust Dent J. 2011 Mar;56(1):2-9. doi: 10.1111/j.1834-7819.2010.01283.x. Epub 2010 Dec 22.
4
[Osteonecrosis of the jaw].[颌骨骨坏死]
Endokrynol Pol. 2011;62 Suppl 3:4-9.
5
Bisphosphonates and osteonecrosis of the jaw: a retrospective study.双膦酸盐与颌骨坏死：一项回顾性研究。
Endocr Pract. 2007 May-Jun;13(3):232-8. doi: 10.4158/EP.13.3.232.
6
A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.关于口服双膦酸盐治疗的骨质疏松症患者颌骨坏死的文献综述：患病率、危险因素及临床特征
Clin Ther. 2007 Aug;29(8):1548-58. doi: 10.1016/j.clinthera.2007.08.008.
7
[Relationship between osteonecrosis of the jaw and bisphosphonate treatment].[颌骨坏死与双膦酸盐治疗之间的关系]
Arh Hig Rada Toksikol. 2010 Sep;61(3):371-80. doi: 10.2478/10004-1254-61-2010-2032.
8
Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.颌骨骨坏死的流行病学和危险因素在癌症患者中。
Ann N Y Acad Sci. 2011 Feb;1218:47-54. doi: 10.1111/j.1749-6632.2010.05771.x. Epub 2010 Sep 28.
9
Osteonecrosis of the jaw associated with bisphosphonate therapy.双膦酸盐治疗相关的颌骨骨坏死
Orthopedics. 2009 Dec;32(12):900. doi: 10.3928/01477447-20091020-16.
10
Osteonecrosis of the jaw related to the use of bisphosphonates.与双膦酸盐类药物使用相关的颌骨骨坏死
Curr Opin Oncol. 2007 Jul;19(4):315-22. doi: 10.1097/CCO.0b013e32819f820b.
引用本文的文献
1
Omega-3 attenuates the severity of medication-related osteonecrosis of the jaws in rats treated with zoledronate.ω-3可减轻唑来膦酸治疗的大鼠颌骨药物性骨坏死的严重程度。
PLoS One. 2025 Mar 26;20(3):e0320413. doi: 10.1371/journal.pone.0320413. eCollection 2025.
2
Histological and morphometrical evaluation of non-critical bone defects after treatment with biomaterial and bisphosphonates.生物材料和双膦酸盐治疗后非关键骨缺损的组织学和形态计量学评估
Med Oral Patol Oral Cir Bucal. 2025 Jul 1;30(4):e491-e498. doi: 10.4317/medoral.27033.
3
A Systematic Review of Laser Photobiomodulation Dosimetry and Treatment Protocols in the Management of Medications-Related Osteonecrosis of the Jaws: A Rationalised Consensus for Future Randomised Controlled Clinical Trials.激光光生物调节剂量学与治疗方案在药物相关性颌骨坏死管理中的系统评价：对未来随机对照临床试验的合理共识
Pharmaceuticals (Basel). 2024 Jul 31;17(8):1011. doi: 10.3390/ph17081011.
4
Engineering a targeted and safe bone anabolic gene therapy to treat osteoporosis in alveolar bone loss.工程化靶向且安全的骨合成基因治疗以治疗牙槽骨丢失性骨质疏松症。
Mol Ther. 2024 Sep 4;32(9):3080-3100. doi: 10.1016/j.ymthe.2024.06.036. Epub 2024 Jun 26.
5
Prediction of wound healing status following dental extraction using Adapted-University of Connecticut osteonecrosis numerical scale: A retrospective study.使用改良的康涅狄格大学骨坏死数值量表预测拔牙后伤口愈合状况：一项回顾性研究。
Health Sci Rep. 2024 Jun 24;7(6):e2184. doi: 10.1002/hsr2.2184. eCollection 2024 Jun.
6
Osteonecrosis of the Jaw Associated with Bisphosphonates Infusion for Treatment of Plasma Cell Myeloma-A Retrospective Observational Study of Northern Portuguese Population.双膦酸盐输注治疗浆细胞骨髓瘤相关颌骨骨坏死——葡萄牙北部人群的一项回顾性观察研究
J Clin Med. 2024 May 2;13(9):2679. doi: 10.3390/jcm13092679.
7
Bisphosphonates and Dental Implants: A Systematic Review and Meta-Analysis.双膦酸盐与牙种植体：一项系统评价与荟萃分析
Materials (Basel). 2023 Sep 5;16(18):6078. doi: 10.3390/ma16186078.
8
Alendronate reduces periosteal microperfusion in vivo.阿仑膦酸盐可降低体内骨膜微灌注。
Heliyon. 2023 Aug 25;9(9):e19468. doi: 10.1016/j.heliyon.2023.e19468. eCollection 2023 Sep.
9
Dentists' Awareness of Medication-Related Osteonecrosis of the Jaw (Risk Factors, Drugs, and Prevention) in the Republic of Croatia.克罗地亚共和国牙医对药物相关性颌骨坏死（风险因素、药物及预防）的认知
Acta Stomatol Croat. 2023 Jun;57(2):121-132. doi: 10.15644/asc57/2/3.
10
Intermittent parathyroid hormone enhances the healing of medication-related osteonecrosis of the jaw lesions in rice rats.间歇性甲状旁腺激素可促进米氏大鼠颌骨药物相关性骨坏死病变的愈合。
Front Med (Lausanne). 2023 Jun 19;10:1179350. doi: 10.3389/fmed.2023.1179350. eCollection 2023.
本文引用的文献
1
Clinical comparison of patients with osteonecrosis of the jaws, with and without a history of bisphosphonates administration.颌骨骨坏死患者，有和无双磷酸盐治疗史的临床比较。
Int J Oral Maxillofac Surg. 2010 Nov;39(11):1097-102. doi: 10.1016/j.ijom.2010.04.054.
2
Bisphosphonate osteonecrosis of the jaw--a literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention.双膦酸盐相关性颌骨坏死——关于英国双膦酸盐政策与国际政策、风险因素及预防的文献综述
Br J Oral Maxillofac Surg. 2011 Jun;49(4):251-7. doi: 10.1016/j.bjoms.2010.05.007. Epub 2010 Jun 7.
3
Bisphosphonates cause osteonecrosis of the jaw-like disease in mice.双膦酸盐可引起小鼠类似下颌骨坏死的疾病。
Am J Pathol. 2010 Jul;177(1):280-90. doi: 10.2353/ajpath.2010.090592. Epub 2010 May 14.
4
Osteonecrosis of the jaw and bevacizumab therapy.颌骨骨坏死与贝伐单抗治疗
Breast Cancer Res Treat. 2010 Jul;122(1):189-91. doi: 10.1007/s10549-010-0933-9. Epub 2010 May 13.
5
Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons.双膦酸盐相关性颌骨坏死：来自日本骨矿研究学会联合工作组委员会、日本骨质疏松症学会、日本牙周病学会、日本口腔颌面放射学会和日本口腔颌面外科学会的立场文件。
J Bone Miner Metab. 2010 Jul;28(4):365-83. doi: 10.1007/s00774-010-0162-7. Epub 2010 Mar 24.
6
Osteonecrosis of the jaw in a patient on Denosumab.使用地诺单抗治疗的患者发生颌骨坏死。
J Oral Maxillofac Surg. 2010 May;68(5):959-63. doi: 10.1016/j.joms.2009.10.010. Epub 2010 Feb 10.
7
American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update.美国口腔颌面外科医师协会关于双膦酸盐相关颌骨坏死的立场文件——2009年更新版
Aust Endod J. 2009 Dec;35(3):119-30. doi: 10.1111/j.1747-4477.2009.00213.x.
8
Bisphosphonate-related osteonecrosis of the jaw: the role of actinomyces.颌骨骨坏死相关性双膦酸盐：放线菌的作用。
Clin Infect Dis. 2009 Dec 1;49(11):1729-32. doi: 10.1086/648075.
9
Osteonecrosis of the jaws induced by anti-RANK ligand therapy.抗RANK配体治疗引起的颌骨骨坏死
Br J Oral Maxillofac Surg. 2010 Apr;48(3):221-3. doi: 10.1016/j.bjoms.2009.08.030.
10
American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update.美国口腔颌面外科医师协会关于双膦酸盐相关颌骨坏死的立场文件——2009年更新版
J Oral Maxillofac Surg. 2009 May;67(5 Suppl):2-12. doi: 10.1016/j.joms.2009.01.009.
Zotero 插件